Business
Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress
ATH434 Phase 2 Data to be Presented at Opening Plenary SessionMELBOURNE, Australia and SAN FRANCISCO, May 07, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that multiple oral and poster presentations related to Alterity’s clinical programs in Multiple System Atrophy (MSA) will be featured at the 2025 International MS
About this update from Alterity Therapeutics Ltd.
[{"type":"image","alt":"ALTERITY THERAPEUTICS LIMITED","displaySize":"","headline":null,"caption":"ALTERITY THERAPEUTICS LIMITED","className":"","disableSlideshowImg":false,"size":{"original":{"width":222,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/5761c8df20b76a3904e54a7775315c62"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aH_lC7vKS4YC2ZvHbgCTDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5761c8df20b76a3904e54a7775315c62","width":222,"height":56}},"lazy":false},{"type":"text","content":"ATH434 Phase 2 Data to be Presented at Opening Plenary Session","length":62,"tagName":"p"},{"type":"text","content":"MELBOURNE, Australia and SAN FRANCISCO, May 07, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that multiple oral and poster presentations related to Alterity’s clinical programs in Multiple System Atrophy (MSA) will be featured at the 2025 International MSA Congress taking place May 9 - 11, 2025 in Boston, MA, USA. The Congress is presented by Mission MSA, a non-profit organization dedicated to improving the quality of life and building hope for people affected by MSA through support services, educational resources, research funding, and community engagement.","length":747,"tagName":"p"},{"type":"text","content":"David Stamler, M.D., Chief Executive Officer of Alterity, commented, “We are excited to play a prominent role at the MSA Congress which brings together a noteworthy group of physicians and scientists as well as patients and care partners, all of whom are focused on advancing MSA research and care. Mission MSA is one of the primary patient education and advocacy organizations for the disease in the U.S., and we are also proud to support the event as a sponsor. We look forward to presenting our double-blind Phase 2 data for ATH434 as well as our bioMUSE natural history study with our colleagues at Vanderbilt University Medical Center. Our clinical advancements in MSA continue to generate significant interest throughout the community, bolstered by the recent Fast Track Designation for ATH434 that was granted by the US FDA.”","length":832,"tagName":"p"},{"type":"table","headerItems":[],"items"...